Search
United Therapeutics Corp
UTHRAdd to Watchlist
549.900USD
+5.570+1.02%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
23.11BMarket Cap
18.79P/E TTM
More Details of United Therapeutics Corp Company
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
United Therapeutics Corp Info
Ticker SymbolUTHR
Company nameUnited Therapeutics Corp
IPO dateJun 17, 1999
CEORothblatt (Martine A)
Number of employees1305
Security typeOrdinary Share
Fiscal year-endJun 17
Address1000 Spring St
CitySILVER SPRING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20910
Phone13016089292
Websitehttps://www.unither.com/
Ticker SymbolUTHR
IPO dateJun 17, 1999
CEORothblatt (Martine A)
Company Executives of United Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
701.73K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.17K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
21.39K
+87.62%
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
--
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.03K
-5.13%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.79K
+15.57%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
--
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
125.00
--
Mr. Raymond C. (Ray) Kurzweil, J.D.
Mr. Raymond C. (Ray) Kurzweil, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
701.73K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
45.17K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
21.39K
+87.62%
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
--
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.03K
-5.13%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.79K
+15.57%
FAQs
Who are the top five shareholders of United Therapeutics Corp?
The top five shareholders of United Therapeutics Corp are: Dr. Martine A. Rothblatt
How many institutions hold shares of United Therapeutics Corp (UTHR)?
As of 2026Q1, 1548 institutions hold shares of United Therapeutics Corp, with a combined market value of approximately 42.91M, accounting for 101.10% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1413631.00.
What is the biggest source of revenue for United Therapeutics Corp?
In 2026Q1, the Tyvaso DPI business generated the highest revenue for United Therapeutics Corp, amounting to 1.29B and accounting for 40.59% of total revenue.
